Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Apr;31(4):544–550. doi: 10.1128/aac.31.4.544

Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus.

S R Turk, C Shipman Jr, R Nassiri, G Genzlinger, S H Krawczyk, L B Townsend, J C Drach
PMCID: PMC174775  PMID: 3037998

Abstract

Seven arabinosyl, 2'-deoxyribosyl, and ribosyl pyrrolo[2,3-d]pyrimidines were evaluated in vitro for activity against human cytomegalovirus and for cytotoxicity in primary and established cell lines of human origin. The parent ribosyl analogs exhibited little antiviral selectivity owing to high cytotoxicity. In contrast, ara-tubercidin, ara-toyocamycin, ara-sangivamycin, and deoxysangivamycin exhibited selectivity between antiviral effect (measured by plaque or titer reduction or both) and cytotoxicity (measured microscopically and by incorporation of radioactive precursors into DNA, RNA, and protein). The selectivity (in vitro therapeutic indexes) for these four compounds ranged from 2 to 40. The two sangivamycin analogs were the most potent and selective. Ara-sangivamycin, for example, inhibited virus replication 10(5)-fold at a concentration (10 microM) which produced only partial inhibition of cell growth and labeled precursor incorporation. The four arabinosyl and deoxyribosyl nucleosides appeared to act by inhibition of viral DNA synthesis as quantitated by DNA-DNA dot blot hybridization. These four analogs also were tested for activity against two strains of type 1 herpes simplex virus by a plaque reduction assay. Unexpectedly, all compounds inhibited herpes simplex virus to a lesser extent than human cytomegalovirus.

Full text

PDF
544

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ACS G., REICH E., MORI M. BIOLOGICAL AND BIOCHEMICAL PROPERTIES OF THE ANALOGUE ANTIBIOTIC TUBERCIDIN. Proc Natl Acad Sci U S A. 1964 Aug;52:493–501. doi: 10.1073/pnas.52.2.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergstrom D. E., Brattesani A. J., Ogawa M. K., Reddy P. A., Schweickert M. J., Balzarini J., De Clercq E. Antiviral activity of C-5 substituted tubercidin analogues. J Med Chem. 1984 Mar;27(3):285–292. doi: 10.1021/jm00369a010. [DOI] [PubMed] [Google Scholar]
  3. Betts R. F. Cytomegalovirus infection in transplant patients. Prog Med Virol. 1982;28:44–64. [PubMed] [Google Scholar]
  4. Biron K. K., Stanat S. C., Sorrell J. B., Fyfe J. A., Keller P. M., Lambe C. U., Nelson D. J. Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2473–2477. doi: 10.1073/pnas.82.8.2473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brdar B., Rifkin D. B., Reich E. Studies of Rous sarcoma virus. Effects of nucleoside analogues on virus synthesis. J Biol Chem. 1973 Apr 10;248(7):2397–2408. [PubMed] [Google Scholar]
  6. Colacino J. M., Lopez C. Efficacy and selectivity of some nucleoside analogs as anti-human cytomegalovirus agents. Antimicrob Agents Chemother. 1983 Oct;24(4):505–508. doi: 10.1128/aac.24.4.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Corey L., Spear P. G. Infections with herpes simplex viruses (2). N Engl J Med. 1986 Mar 20;314(12):749–757. doi: 10.1056/NEJM198603203141205. [DOI] [PubMed] [Google Scholar]
  8. De Clercq E., Bernaerts R., Bergstrom D. E., Robins M. J., Montgomery J. A., Holy A. Antirhinovirus activity of purine nucleoside analogs. Antimicrob Agents Chemother. 1986 Mar;29(3):482–487. doi: 10.1128/aac.29.3.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dolin R. Antiviral chemotherapy and chemoprophylaxis. Science. 1985 Mar 15;227(4692):1296–1303. doi: 10.1126/science.2983421. [DOI] [PubMed] [Google Scholar]
  10. Estes J. E., Huang E. S. Stimulation of cellular thymidine kinases by human cytomegalovirus. J Virol. 1977 Oct;24(1):13–21. doi: 10.1128/jvi.24.1.13-21.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fiddian A. P., Brigden D., Yeo J. M., Hickmott E. A. Acyclovir: an update of the clinical applications of this antiherpes agent. Antiviral Res. 1984 Jun;4(3):99–117. doi: 10.1016/0166-3542(84)90011-1. [DOI] [PubMed] [Google Scholar]
  12. Field A. K., Davies M. E., DeWitt C., Perry H. C., Liou R., Germershausen J., Karkas J. D., Ashton W. T., Johnston D. B., Tolman R. L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4139–4143. doi: 10.1073/pnas.80.13.4139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Freitas V. R., Smee D. F., Chernow M., Boehme R., Matthews T. R. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob Agents Chemother. 1985 Aug;28(2):240–245. doi: 10.1128/aac.28.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gadler H. Nucleic acid hybridization for measurement of effects of antiviral compounds on human cytomegalovirus DNA replication. Antimicrob Agents Chemother. 1983 Sep;24(3):370–374. doi: 10.1128/aac.24.3.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Glazer R. I., Peale A. L. Comparison between the inhibitory activities of sangivamycin and thiosangivamycin on nuclear ribonucleic acid synthesis in L1210 cells in vitro. Biochem Pharmacol. 1980 Feb;29(3):305–310. doi: 10.1016/0006-2952(80)90505-5. [DOI] [PubMed] [Google Scholar]
  16. Hirai K., Furukawa T., Plotkin S. A. Induction of DNA Polymerase in WI-38 and guinea pig cells infected with human cytomegalovirus (HCMV). Virology. 1976 Mar;70(1):251–255. doi: 10.1016/0042-6822(76)90266-x. [DOI] [PubMed] [Google Scholar]
  17. Hirsch M. S., Schooley R. T. Drug therapy. Treatment of herpesvirus infections. N Engl J Med. 1983 Oct 27;309(17):1034–1039. doi: 10.1056/NEJM198310273091706. [DOI] [PubMed] [Google Scholar]
  18. Huang E. S. Human cytomegalovirus. III. Virus-induced DNA polymerase. J Virol. 1975 Aug;16(2):298–310. doi: 10.1128/jvi.16.2.298-310.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kit S. Viral-associated and induced enzymes. Pharmacol Ther B. 1979;4(3):501–585. doi: 10.1016/0163-7258(79)90004-4. [DOI] [PubMed] [Google Scholar]
  20. Macher A. M., Reichert C. M., Straus S. E., Longo D. L., Parrillo J., Lane H. C., Fauci A. S., Rook A. H., Manischewitz J. F., Quinnan G. V., Jr Death in the AIDS patient: role of cytomegalovirus. N Engl J Med. 1983 Dec 8;309(23):1454–1454. doi: 10.1056/NEJM198312083092312. [DOI] [PubMed] [Google Scholar]
  21. Mar E. C., Cheng Y. C., Huang E. S. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983 Oct;24(4):518–521. doi: 10.1128/aac.24.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mar E. C., Patel P. C., Cheng Y. C., Fox J. J., Watanabe K. A., Huang E. S. Effects of certain nucleoside analogues on human cytomegalovirus replication in vitro. J Gen Virol. 1984 Jan;65(Pt 1):47–53. doi: 10.1099/0022-1317-65-1-47. [DOI] [PubMed] [Google Scholar]
  23. Marker S. C., Howard R. J., Groth K. E., Mastri A. R., Simmons R. L., Balfour H. H., Jr A trial of vidarabine for cytomegalovirus infection in renal transplant patients. Arch Intern Med. 1980 Nov;140(11):1441–1444. [PubMed] [Google Scholar]
  24. Maruyama T., Wotring L. L., Townsend L. B. Pyrrolopyrimidine nucleosides. 18. Synthesis and chemotherapeutic activity of 4-amino-7-(3-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine-5-carboxamide (3'-deoxysangivamycin) and 4-amino-7-(2-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d] pyrimidine-5-carboxamide (2'-deoxysangivamycin). J Med Chem. 1983 Jan;26(1):25–29. doi: 10.1021/jm00355a006. [DOI] [PubMed] [Google Scholar]
  25. Meyers J. D., McGuffin R. W., Bryson Y. J., Cantell K., Thomas E. D. Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon. J Infect Dis. 1982 Jul;146(1):80–84. doi: 10.1093/infdis/146.1.80. [DOI] [PubMed] [Google Scholar]
  26. OWEN S. P., SMITH C. G. CYTOTOXICITY AND ANTITUMOR PROPERTIES OF THE ABNORMAL NUCLEOSIDE TUBERCIDIN (NSC-56408). Cancer Chemother Rep. 1964 Mar;36:19–22. [PubMed] [Google Scholar]
  27. Shepp D. H., Dandliker P. S., Meyers J. D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med. 1986 Jan 23;314(4):208–212. doi: 10.1056/NEJM198601233140404. [DOI] [PubMed] [Google Scholar]
  28. Shipman C., Jr Evaluation of 4-(2-hydroxyethyl)-1-piperazineëthanesulfonic acid (HEPES) as a tissue culture buffer. Proc Soc Exp Biol Med. 1969 Jan;130(1):305–310. doi: 10.3181/00379727-130-33543. [DOI] [PubMed] [Google Scholar]
  29. Shipman C., Jr, Smith S. H., Carlson R. H., Drach J. C. Antiviral activity of arabinosyladenine and arabinosylhypoxanthine in herpes simplex virus-infected KB cells: selective inhibition of viral deoxyribonucleic acid synthesis in synchronized suspension cultures. Antimicrob Agents Chemother. 1976 Jan;9(1):120–127. doi: 10.1128/aac.9.1.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Thomsen D. R., Stinski M. F. Cloning of the human cytomegalovirus genome as endonuclease XbaI fragments. Gene. 1981 Dec;16(1-3):207–216. doi: 10.1016/0378-1119(81)90077-9. [DOI] [PubMed] [Google Scholar]
  31. Wade J. C., Hintz M., McGuffin R., Springmeyer S. C., Connor J. D., Meyers J. D. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med. 1982 Jul 20;73(1A):249–256. doi: 10.1016/0002-9343(82)90100-0. [DOI] [PubMed] [Google Scholar]
  32. Wahren B., Rudén U., Gadler H., Oberg B., Eriksson B. Activity of the cytomegalovirus genome in the presence of PPi analogs. J Virol. 1985 Dec;56(3):996–1001. doi: 10.1128/jvi.56.3.996-1001.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES